Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.

MLA

Vesikari, Timo, et al. “Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-Label, Randomized Trials.” The Pediatric Infectious Disease Journal, vol. 34, no. 7, July 2015, pp. 774–82. EBSCOhost, https://doi.org/10.1097/INF.0000000000000709.

APA

Vesikari, T., Richardus, J. H., Berglund, J., Korhonen, T., Flodmark, C.-E., Lindstrand, A., Silfverdal, S. A., Bambure, V., Caplanusi, A., Dieussaert, I., Roy-Ghanta, S., & Vaughn, D. W. (2015). Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials. The Pediatric Infectious Disease Journal, 34(7), 774–782. https://doi.org/10.1097/INF.0000000000000709

Chicago

Vesikari, Timo, Jan Hendrik Richardus, Johan Berglund, Tiina Korhonen, Carl-Erik Flodmark, Ann Lindstrand, Sven Arne Silfverdal, et al. 2015. “Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-Label, Randomized Trials.” The Pediatric Infectious Disease Journal 34 (7): 774–82. doi:10.1097/INF.0000000000000709.